Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG56-VIII
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
MG56-VIII is an investigational **mannan-conjugated polymerized grass-pollen allergoid** allergen immunotherapy attributed to Inmunotek. The MG56 material evaluated clinically comprised a 50:50 mixture of *Phleum pratense* and *Dactylis glomerata* pollen allergoids conjugated with mannan and was administered by subcutaneous or sublingual routes for grass pollen-induced allergic rhinitis and allergic rhinoconjunctivitis. The intended mechanism is allergen-specific immune tolerance induction through enhanced dendritic-cell engagement and downstream regulatory immune responses. ([frontiersin.org](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1431351/full))
02
Targets
MRC1 (Mannose Receptor C-type 1)T-cell receptor recognizing Malassezia globosa allergen 1 (Mala g 1) peptide 56–70–MHC class II complexBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on MG56-VIII.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG56-VIII.